Last update 23 Jan 2025

Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)

Holding Company|
2017|
Shanghai Shi, China
|
www.lynkpharma.com

Overview

Related

1
Drugs associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
LNK-01002
Target
FLT3 x JAK1 x JAK2
Mechanism
FLT3 inhibitors [+2]
Active Org.
Lynk Pharmaceuticals Co., LtdLynk Pharmaceuticals Co., LtdStartup
Originator Org.
Lynk Pharmaceuticals Co., LtdLynk Pharmaceuticals Co., LtdStartup
Active Indication
Primary Myelofibrosis
Inactive Indication
Acute Myeloid Leukemia [+3]
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
NCT06085534
/ CompletedPhase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of LNK01001 Capsule in Patients With Ankylosing Spondylitis
NCT04896112
/ WithdrawnPhase 1
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
100 Clinical Results associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
Login to view more data
0 Patents (Medical) associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
Login to view more data
100 Deals associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
Login to view more data
100 Translational Medicine associated with Lingke Pharmaceutical (Hangzhou) Co., Ltd. (China)
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
LNK-01002
 ( FLT3 x JAK1 x JAK2 )		Primary Myelofibrosis
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free